SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
BINDU KANAPURU (BETHESDA)
FOOD AND DRUG ADMINISTRATION
Food and Drug Administration, Bethesda, USA
Thirteen drugs are approved for the treatment of MM and several novel combination regimens have been
approved for patients with newly diagnosed and relapsed or refractory MM. The presentation will
highlight FDA drug approval pathways, endpoints and brief discussion on the caveats in the use of earlier
endpoints Trial design, control arms and the appropriateness of the combination regimens in recent trials
supporting approval will also be discussed. The presentation will also highlight recent data on under-representation
of racial and ethnic minorities in multiple myeloma and approach to obtaining safety and
efficacy data on racial and ethnic minorities